Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemia.
Jin Q, Harris E, Myers JA, Mehmood R, Cotton A, Shirnekhi HK, Baggett DW, Wen JQ, Schild AB, Bhansali RS, Klein J, Narina S, Pieters T, Yoshimi A, Pruett-Miller SM, Kriwacki R, Abdel-Wahab O, Malinge S, Ntziachristos P, Obeng EA, Crispino JD.
Jin Q, et al. Among authors: mehmood r.
Blood. 2024 Sep 24:blood.2024024281. doi: 10.1182/blood.2024024281. Online ahead of print.
Blood. 2024.
PMID: 39316649
Free article.